New JAK2 inhibitors for myeloproliferative neoplasms (Q37869152)

24 August 2017

1 reference

title

New JAK2 inhibitors for myeloproliferative neoplasms (English)

1 reference

24 August 2017

2

Srdan Verstovsek

1 reference

24 August 2017

author name string

Alfonso Quintás-Cardama

series ordinal

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

27 April 2011

1 reference

Expert Opinion on Investigational Drugs

24 August 2017

published in

1 reference

24 August 2017

volume

20

1 reference

24 August 2017

issue

7

1 reference

24 August 2017

page(s)

961-972

1 reference

The chronic myeloproliferative disorders: clonality and clinical heterogeneity

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Polycythemia vera: myths, mechanisms, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Pathogenesis and management of essential thrombocythemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

How I treat patients with polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

The haematocrit and platelet target in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Choosing between stem cell therapy and drugs in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Advances in the therapy of chronic idiopathic myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

How I treat symptomatic splenomegaly in patients with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Letter: Tinel sign in carpal-tunnel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Endogenous Erythroid Colony Formation by Peripheral Blood Mononuclear Cells from Patients with Myelofibrosis and Polycythemia Vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Polycythemia vera: stem-cell and probable clonal origin of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Identification of an acquired JAK2 mutation in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Mutation in TET2 in myeloid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

LNK mutations in JAK2 mutation-negative erythrocytosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Mutations of ASXL1 gene in myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Taxing sugar-sweetened beverages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Regulation of the Jak2 tyrosine kinase by its pseudokinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Expression of Bcl-x in erythroid precursors from patients with polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Characterization of murine JAK2V617F-positive myeloproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

JAK mutations in high-risk childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Identification of somatic JAK1 mutations in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Activating alleles of JAK3 in acute megakaryoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

The JAK2 V617F mutation in de novo acute myelogenous leukemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the JAK/STAT pathway in kidney transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

JAK2 Mutations are present in all cases of polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579560

10.1517/13543784.2011.579560

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference